To patients, the only ones that matter, we are Trusted Quality Care
For the over 700,000 Canadians that benefit from radiopharmaceuticals annually, their last concern should be the veracity of these crucial medicines brought to bear during their treatment. We will do everything in our power to provide a consistent supply of the highest quality radiopharmaceuticals in the world and deliver them on time. We currently deliver 99.6% certainty. Good, but we can do better because ultimately we’re here to be your Trusted Quality Care Partner.
Spect Radiopharmaceuticals
André Gagnon, President
ISOLOGIC has taken a leadership position in supplying the Canadian nuclear medicine community with clinically relevant radiopharmaceuticals. Our proven success in developing and commercializing innovative imaging agents provides strong evidence of our willingness to bring forward breakthrough radiopharmaceuticals to market.
With state-of-the-art facilities across Central Canada, and strategic alliances with world-renowned university research hospitals and dedicated expert resources, ISOLOGIC is ready to expand its offering to include the next generation of PET and SPECT compounds and provide nuclear medicine centers with the most significant tools to improve patient care.
Management team
David Paradis
Vice-President Finance
Christine Henault
Vice-President Sales and Marketing
Annette Proulx
Vice-President of Operations
Stephane Martin
Sr. Director of CMC / Quality & New Products Development
Vasa Sindolic
Senior Director Cyclotron and Engineering
Noteworthy News
News, Insight, Education